On November 4, Bayer China announced that the State Drug Administration has approved Hercinol® monotherapy, a novel targeted treatment for lung cancer, to treat adult patients with unresectable locally advanced or metastatic non-small cell lung cancer with HER2 activating mutations.

Zhitongcaijing · 6d ago
On November 4, Bayer China announced that the State Drug Administration has approved Hercinol® monotherapy, a novel targeted treatment for lung cancer, to treat adult patients with unresectable locally advanced or metastatic non-small cell lung cancer with HER2 activating mutations.